Kumarasamy N, Venkatesh Kartik K, Devaleenol Bella, Poongulali S, Mothi S N, Solomon Suniti
YRG Centre for AIDS Research and Education, VHS, Chennai 600113, Tamil Nadu, India.
J Trop Pediatr. 2009 Jun;55(3):155-9. doi: 10.1093/tropej/fmn080. Epub 2008 Oct 1.
HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with >18 months of follow-up on HAART at a tertiary HIV care program. The median CD4 cell count at enrolment was 290 cells microl(-1) and at treatment initiation was 225 cells microl(-1). Patients demonstrated a significant rise in their CD4 cell counts between treatment initiation and after 6 months (701 cells microll(-1); p = 0.007), 12 months (741 cells microl(-1); p = 0.037), and 18 months of therapy (718 cells microl(-1); p = 0.005). The most common adverse events to therapy were nausea (20.9%) and rash (25.4%). Over one-fifth of patients (25.4%) substituted therapy due to toxicities and 19.4% of patients switched to second-line protease inhibitor-containing regimens. In this South Indian pediatric cohort, generic HAART was safe, effective and relatively well tolerated.
在资源有限的环境中，感染艾滋病毒的儿童越来越多地能够获得高效抗逆转录病毒疗法（HAART），但记录在案的纵向数据仍然有限。我们旨在研究在一个三级艾滋病毒护理项目中，67名接受HAART治疗且随访时间超过18个月的南印度感染艾滋病毒儿童的临床和免疫结果。入组时的CD4细胞计数中位数为290个/微升，开始治疗时为225个/微升。患者在开始治疗后6个月（701个/微升；p = 0.007）、12个月（741个/微升；p = 0.037）和18个月（718个/微升；p = 0.005）时，CD4细胞计数显著上升。治疗中最常见的不良事件是恶心（20.9%）和皮疹（25.4%）。超过五分之一的患者（25.4%）因毒性反应更换治疗方案，19.4%的患者改用含二线蛋白酶抑制剂的治疗方案。在这个南印度儿科队列中，通用型HAART安全、有效且耐受性相对良好。
